Intellia Therapeutics (NTLA) Releases Quarterly Earnings Results

Intellia Therapeutics (NASDAQ:NTLA) posted its quarterly earnings results on Wednesday. The company reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by ($0.16), reports. The business had revenue of $6.70 million during the quarter, compared to analyst estimates of $8.84 million. Intellia Therapeutics had a negative return on equity of 28.01% and a negative net margin of 215.92%. The business’s revenue was up 19.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.31) EPS.

Shares of Intellia Therapeutics (NASDAQ NTLA) opened at $32.43 on Wednesday. Intellia Therapeutics has a 1 year low of $11.15 and a 1 year high of $35.99. The firm has a market cap of $1,200.21, a price-to-earnings ratio of -21.29 and a beta of 2.42.

Several equities research analysts have recently issued reports on the stock. Barclays lifted their price objective on shares of Intellia Therapeutics from $33.00 to $46.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 7th. JMP Securities assumed coverage on shares of Intellia Therapeutics in a research report on Thursday, March 8th. They set an “outperform” rating for the company. Oppenheimer reaffirmed a “hold” rating on shares of Intellia Therapeutics in a research report on Monday, December 18th. BidaskClub raised shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Finally, ValuEngine cut shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 15th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $33.00.

In related news, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $26.78, for a total value of $14,746,273.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.80% of the stock is owned by insiders.

A hedge fund recently raised its stake in Intellia Therapeutics stock. State Street Corp boosted its stake in Intellia Therapeutics Inc (NASDAQ:NTLA) by 52.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 164,798 shares of the company’s stock after acquiring an additional 56,363 shares during the period. State Street Corp owned about 0.46% of Intellia Therapeutics worth $2,638,000 as of its most recent SEC filing. 68.14% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Intellia Therapeutics (NTLA) Releases Quarterly Earnings Results” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Earnings History for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply